

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/088,467	06/24/2002	Kenneth D. Tew	FCCC.99-08US	8802
110 75	7590 03/25/2004		EXAMINER	
DANN, DORFMAN, HERRELL & SKILLMAN 1601 MARKET STREET			NICHOLS, CH	RISTOPHER J
SUITE 2400			ART UNIT	PAPER NUMBER
PHILADELPH	IA, PA 19103-2307		1647	
			DATE MAILED: 03/25/2004	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/088,467	TEW ET AL.
Office Action Summary	Examiner	Art Unit
	Christopher J Nichols, Ph.D.	1647
The MAILING DATE of this commun. Period for Reply	ication appears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNI - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this community if the period for reply specified above is less than thirty (3). If NO period for reply is specified above, the maximum states a specified above, the maximum states are reply in the period for reply any reply received by the Office later than three months a earned patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no event, however, may a reply nunication. 0) days, a reply within the statutory minimum of thirty (3) atutory period will apply and will expire SIX (6) MONTHS will, by statute, cause the application to become ABANI	by be timely filed O) days will be considered timely. S from the mailing date of this communication. DONED (35 U.S.C. § 133).
Status		
3) Since this application is in condition	2b)⊠ This action is non-final.	·
Disposition of Claims		
4) ⊠ Claim(s) <u>1-25</u> is/are pending in the a 4a) Of the above claim(s) is/ar 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-25</u> are subject to restriction	re withdrawn from consideration.	
Application Papers		
•	a) accepted or b) objected to by ction to the drawing(s) be held in abeyance, the correction is required if the drawing(s)	. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
2. Certified copies of the priority3. Copies of the certified copies	documents have been received. documents have been received in Appl of the priority documents have been rec nal Bureau (PCT Rule 17.2(a)).	lication No ceived in this National Stage
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (P' 3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date		mary (PTO-413) fail Date mal Patent Application (PTO-152)

Application/Control Number: 10/088,467

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

- 1. Restriction is required under 35 U.S.C. 121 and 372.
- 2. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.
- 3. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-4, 6-7, and 11-16, drawn to SEQ ID NO: 1, host cells, and vectors comprising same.

Group 2, claim(s) 5 and 17, drawn to RNA of SEQ ID NO: 1, anti-sense complement of SEQ ID NO: 1, and host cells comprising same.

Group 3, claim(s) 8-10, drawn to antibodies.

Group 4, claim(s) 18-21, drawn to transgenic animals.

Group 5, claim(s) 22-24, drawn to a method for screening a test compound.

Group 6, claim(s) 25, drawn to a kit for detecting the presence of human ABCA2-encoding nucleic acids.

Art Unit: 1647

4. According to PCT Rule 13.2, unity of invention exists only when there is a shared same or corresponding special technical feature among the claimed inventions. All the groupings are directed to inventions related to SEQ ID NO: 1 but each group has a different special technical feature not shared by the remaining groups.

Group 1 has the special technical feature of SEQ ID NO: 1 allelic variants not shared by any of the remaining groups.

Group 2 has the special technical feature of anti-sense RNA not shared by any of the remaining groups.

Group 3 has the special technical feature of <u>antibodies</u> not shared by any of the remaining groups.

Group 4 has the special technical feature of transgenic animals not shared by any of the remaining groups.

Group 5 has the special technical feature of screening test compounds not shared by any of the remaining groups.

Art Unit: 1647

+· 1647

Group 6 has the special technical feature of <u>oligonucleotides primers</u> not shared by any of the remaining groups.

- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 8. The Examiner has required restriction between product and method claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn method claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Method claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Application/Control Number: 10/088,467

Art Unit: 1647

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted

after allowance are governed by 37 CFR 1.312.

9. In the event of rejoinder, the requirement for restriction between the product claims and

the rejoined method claims will be withdrawn, and the rejoined method claims will be fully

examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined

claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102,

103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction

requirement between product claims and method claims may be maintained. Withdrawn method

claims that are not commensurate in scope with an allowed product claim will not be rejoined.

See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re

Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to

retain the right to rejoinder in accordance with the above policy, Applicant is advised that the

method claims should be amended during prosecution either to maintain dependency on the

method claims or to otherwise include the limitations of the product claims. Failure to do so

may result in a loss of the right to rejoinder.

10. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121

does not apply where the restriction requirement is withdrawn by the Examiner before the patent

issues. See MPEP § 804.01.

Page 5

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Christopher James Nichols**, **Ph.D.** whose telephone number is **(571) 272-0889**. The examiner can normally be reached on Monday through Friday, 8:00 AM to 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Gary Kunz**, **Ph.D.** can be reached on **(571) 272-0887**.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CJN

March 19, 2004

ELIZABETH KEMMERER PRIMARY EXAMINER

Elyaber C. Kemmeres